Test All for Hepatitis B Virus: Link to Care and Treatment if Quantitative DNA Positive, Vaccinate if Susceptible.

[1]  Noele P. Nelson,et al.  Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 , 2023, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[2]  J. Kao,et al.  Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection , 2023, Clinical and molecular hepatology.

[3]  D. Serraino,et al.  Extrahepatic Manifestations of Chronic HBV Infection and the Role of Antiviral Therapy , 2022, Journal of clinical medicine.

[4]  F. Zoulim,et al.  Nomenclature of HBV core protein-targeting antivirals , 2022, Nature Reviews Gastroenterology & Hepatology.

[5]  Bhavna S. Paratala,et al.  Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B , 2022, Hepatology communications.

[6]  M. El-Sayed,et al.  Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings , 2022, World journal of hepatology.

[7]  G. Raimondo,et al.  Occult Hepatitis B Virus Infection: An Update , 2022, Viruses.

[8]  Z. Duan,et al.  Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients , 2022, International journal of medical sciences.

[9]  Q. Xue,et al.  Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management , 2022, Infectious Microbes and Diseases.

[10]  M. Ghany,et al.  Review article: hepatitis B—current and emerging therapies , 2022, Alimentary pharmacology & therapeutics.

[11]  H. Manley,et al.  A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis. , 2022, Nephrology, Dialysis and Transplantation.

[12]  S. McPherson,et al.  Viral hepatitis in 2021: The challenges remaining and how we should tackle them , 2022, World journal of gastroenterology.

[13]  H. Janssen,et al.  Getting to HBV cure: The promising paths forward , 2022, Hepatology.

[14]  David Z. Pan,et al.  Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations with Implications on Host Gene Dysregulation. , 2022, Gastroenterology.

[15]  M. Elmoghazy,et al.  Metabolic dysfunction-associated fatty liver disease from definition to complications , 2021, Medical Journal of Viral Hepatitis.

[16]  K. Haruma,et al.  Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases , 2021, World journal of gastroenterology.

[17]  V. D. de Paula,et al.  Occult Hepatitis B virus (HBV) infection and challenges for hepatitis elimination: A literature review , 2021, Journal of applied microbiology.

[18]  Z. Younossi,et al.  Causes of Death in Patients with Non-alcoholic Fatty Liver Disease (NAFLD), Alcoholic Liver Disease and Chronic Viral Hepatitis B and C. , 2021, Annals of hepatology.

[19]  M. Yuen,et al.  Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial , 2021, Nature Medicine.

[20]  Panyavee Pitisuttithum,et al.  Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) , 2021, Journal of clinical and translational hepatology.

[21]  D. Dieterich,et al.  Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  Xinyue Chen,et al.  Functional cure for chronic hepatitis B: accessibility, durability, and prognosis , 2021, Virology Journal.

[23]  F. Zoulim,et al.  Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections. , 2021, Journal of hepatology.

[24]  M. Balakrishnan,et al.  Global Epidemiology of Chronic Liver Disease , 2021, Clinical liver disease.

[25]  G. Lee,et al.  CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update , 2021, Expert review of vaccines.

[26]  Steven S. Wong,et al.  An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States , 2021, Hepatology.

[27]  M. Mugavero,et al.  Practice Transformation in HIV Primary Care: Perspectives of Coaches and Champions in the Southeast United States , 2021, Journal of primary care & community health.

[28]  S. Ahn,et al.  Hepatitis B Virus Cure: Targets and Future Therapies , 2020, International journal of molecular sciences.

[29]  S. Ahn,et al.  Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic HBV Infection. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  Noele P. Nelson,et al.  A Population‐Based Intervention to Improve Care Cascades of Patients With Hepatitis C Virus Infection , 2020, Hepatology communications.

[31]  Yahiya Y. Syed,et al.  Bulevirtide: First Approval , 2020, Drugs.

[32]  Min Zheng,et al.  Hepatitis B virus persistence and reactivation , 2020, BMJ.

[33]  Anurag Maheshwari,et al.  Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease , 2020, Digestive Diseases and Sciences.

[34]  M. Yuen,et al.  Role of Core/Capsid Inhibitors in Functional Cure Strategies for Chronic Hepatitis B , 2020, Current Hepatology Reports.

[35]  W. Kim,et al.  Prevalence of Chronic Hepatitis B Virus Infection in the United States. , 2020, The American journal of gastroenterology.

[36]  M. Manns,et al.  RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection , 2020, Hepatology.

[37]  Hashem B. El-Serag,et al.  Epidemiology of Hepatocellular Carcinoma , 2020, Hepatology.

[38]  J. Smith-Palmer,et al.  Impact of Stigma on People Living with Chronic Hepatitis B , 2020, Patient related outcome measures.

[39]  M. Bazinet,et al.  Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. , 2020, Gastroenterology.

[40]  J. Kao,et al.  Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy , 2020, Clinical Microbiology Reviews.

[41]  T. Asselah,et al.  Future treatments for hepatitis delta virus infection , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[42]  J. Feld,et al.  Review article: clinical pharmacology of current and investigational hepatitis B virus therapies , 2019, Alimentary pharmacology & therapeutics.

[43]  J. H. Kim,et al.  The risk of hepatocellular carcinoma among chronic hepatitis B virus‐infected patients outside current treatment criteria , 2019, Journal of viral hepatitis.

[44]  Anh-Hoa Nguyen,et al.  Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study. , 2019, Journal of hepatology.

[45]  W. Talloen,et al.  Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. , 2019, Gastroenterology.

[46]  G. Wong,et al.  Current Knowledge of Occult Hepatitis B Infection and Clinical Implications , 2019, Seminars in Liver Disease.

[47]  S. Kedia,et al.  Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern , 2019, The Indian journal of medical research.

[48]  N. Tang,et al.  Recent Advances in HBV Reactivation Research , 2018, BioMed research international.

[49]  J. Pawlotsky,et al.  Chronic hepatitis B virus infection , 2018, The Lancet.

[50]  M. Stepanova,et al.  Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient‐Reported Outcomes , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  C. Spearman.  Towards the elimination of hepatitis B and hepatocellular carcinoma. , 2018, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[52]  C. Fan,et al.  Hepatitis B virus and risk of non‐Hodgkin lymphoma: An updated meta‐analysis of 58 studies , 2018, Journal of viral hepatitis.

[53]  Ding‐Shinn Chen,et al.  Hepatitis B virus infection , 2018, Nature Reviews Disease Primers.

[54]  S. Kottilil,et al.  Chronic Hepatitis B Infection: A Review , 2018, JAMA.

[55]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[56]  Myeong Jun Song,et al.  Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region—the GO ASIA initiative , 2018, Alimentary pharmacology & therapeutics.

[57]  Noele P. Nelson,et al.  Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices , 2018, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[58]  D. Candotti,et al.  Occult hepatitis B infection and transfusion-transmission risk. , 2017, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[59]  J. Rich,et al.  Epidemiology and Treatment of Hepatitis B in Prisoners , 2017, Current Hepatology Reports.

[60]  N. Xia,et al.  Detection of HBV Covalently Closed Circular DNA , 2017, Viruses.

[61]  Martin A. Sehr,et al.  Markov modeling in hepatitis B screening and linkage to care , 2017, Theoretical Biology and Medical Modelling.

[62]  Noele P. Nelson,et al.  Surveillance of Vaccination Coverage among Adult Populations — United States, 2015 , 2017, Morbidity and mortality weekly report. Surveillance summaries.

[63]  T. Liang,et al.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. , 2017, Gastroenterology.

[64]  B. Ruan,et al.  [Clinical value of health-related quality of life evaluation in community patients with hepatitis B]. , 2017, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[65]  Noele P. Nelson,et al.  Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. , 2016, Clinics in liver disease.

[66]  W. Ayoub,et al.  Hepatitis B Management in the Pregnant Patient: An Update , 2016, Journal of clinical and translational hepatology.

[67]  G. Papatheodoridis,et al.  The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy , 2016, Clinical and molecular hepatology.

[68]  M. Nguyen,et al.  Serum Alanine Aminotransferase and Hepatitis B DNA Flares in Pregnant and Postpartum Women with Chronic Hepatitis B , 2016, The American Journal of Gastroenterology.

[69]  V. Pattullo.  Prevention of Hepatitis B reactivation in the setting of immunosuppression , 2016, Clinical and molecular hepatology.

[70]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[71]  M. Nassal.  HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B , 2015, Gut.

[72]  A. Lok,et al.  Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. , 2015, Journal of hepatology.

[73]  F. Negro.  Hepatitis D virus coinfection and superinfection. , 2014, Cold Spring Harbor perspectives in medicine.

[74]  A. Gaggar,et al.  Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. , 2014, Vaccine.

[75]  R. Bartenschlager,et al.  Strategies to inhibit entry of HBV and HDV into hepatocytes. , 2014, Gastroenterology.

[76]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[77]  K. Kowdley,et al.  Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin , 2012, Hepatology.

[78]  Wei Ming Dariotis,et al.  Destigmatizing Hepatitis B in the Asian American Community: Lessons Learned from the San Francisco Hep B Free Campaign , 2012, Journal of Cancer Education.

[79]  E. Chang,et al.  San Francisco Hep B Free: A Grassroots Community Coalition to Prevent Hepatitis B and Liver Cancer , 2010, Journal of Community Health.

[80]  Sang-Heon Cho,et al.  Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids , 2010, Respirology.

[81]  U. Mihm,et al.  Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function , 2009, Hepatology.

[82]  P. Cacoub,et al.  Hepatitis B-related autoimmune manifestations. , 2009, Rheumatic diseases clinics of North America.

[83]  P. van Damme,et al.  The global impact of vaccination against hepatitis B: a historical overview. , 2008, Vaccine.

[84]  K. Simon,et al.  Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. , 2008, Gastroenterology.

[85]  S. Baig,et al.  The extrahepatic manifestations of hepatitis B virus. , 2008, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[86]  H. Chae,et al.  Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV) , 2008, Hepatology international.

[87]  H. Thomas,et al.  Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). , 2007, Journal of hepatology.

[88]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[89]  M. Alter,et al.  A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States , 2006, Pediatrics.

[90]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[91]  B. McMahon,et al.  Chronic hepatitis B. , 2002, The New England journal of medicine.

[92]  E. Tabor.  Hepatocellular carcinoma: global epidemiology. , 2001, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[93]  G. Guyatt,et al.  Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease , 1999, Gut.

[94]  World Health Organization.  Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. , 2019, Vaccine.

[95]  K. Reddy,et al.  American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. , 2015, Gastroenterology.

[96]  Y. Falck‐Ytter,et al.  American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .

[97]  M. Norouzi,et al.  The pigeonhole of occult hepatitis B. , 2014, Acta medica Iranica.

[98]  Hong Zhao,et al.  Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B , 2010, Inflammation Research.

[99]  A. Lok,et al.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). , 2003, Journal of hepatology.